Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Amiprilose

Amiprilose
Contact us for more batch information
Select Batch
Purity:100%
ee:100%

Amiprilose

Catalog No. T25080Cas No. 56824-20-5
Amiprilose (SM 1213) has anti-inflammatory activity and inhibits the proliferation of a variety of hyperproliferative cell types.Amiprilose induces lymphokine-induced macrophage activation and may be used in studies of rheumatoid arthritis and psoriasis.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$293In Stock
5 mg$722In Stock
10 mg$987In Stock
25 mg$1,520In Stock
50 mg$1,980In Stock
100 mg$2,500In Stock
Bulk & Custom
Add to Cart

Product Introduction

Bioactivity
Description
Amiprilose (SM 1213) has anti-inflammatory activity and inhibits the proliferation of a variety of hyperproliferative cell types.Amiprilose induces lymphokine-induced macrophage activation and may be used in studies of rheumatoid arthritis and psoriasis.
In vitro
Low concentrations of Amiprilose hydrochloride (1-100 μg/ml) stimulated proliferation of mouse thymocytes and enhanced IL-1-stimulated proliferative responses in human synovial fibroblasts.[1];In all three models, Amiprilose hydrochloride at concentrations of 0.1% (w/v) or less was not toxic to fibroblasts and keratinocytes and did not interfere with the differentiation of skin equivalents and developing skin equivalents. When tested in skin equivalents, Amiprilose hydrochloride concentrations between 0.1% and 0.5% resulted in altered fibroblast morphology with large intracellular vacuoles, and concentrations above 5% were toxic. In mature skin equivalents, Amiprilose hydrochloride at concentrations of 1% to 10% affected the epidermis in addition to changes in fibroblast morphology. During differentiation, epidermal keratinocytes are also affected when 0.5% Amiprilose hydrochloride is present in developing skin equivalents.[2]
In vivo
In 8 consecutive experiments, 90 Louvain (LOU) rats and 91 Sprague-Dawley (SD) rats were immunized with chick type II collagen and administered amiprilose HCl aqueous (1 mg/mL). In LOU rats, the incidence of arthritis was 7/46 (15%) in the amiprilose HCl group compared with 16/44 (36%) in the aqueous group (P less than 0.01). In SD rats, the incidence of arthritis was 28/46 (60%) in the experimental group and 33/45 (73%) in the control group (p greater than NS), but the incidence of arthritis was significantly lower in the experimental group on days 16 and 21 (p less than 0.03). In the LOU assay, amiprilose HCl did not affect antibody titers or delayed hypersensitivity to collagen, nor did it affect the distribution of T cell subsets. At a nontoxic concentration of 1 mg/mL, amiprilose HCl reduced 3H thymidine incorporation in cultured rabbit synovial fibroblasts by 78% and resulted in the presence of numerous intracytoplasmic granules/vacuoles. amiprilose HCl system also reduced prostaglandin E2 levels in rabbit synovial cell supernatant in a dose-related manner by as much as 73% without affecting collagenase activity. collagenase activity.[5]
AliasSM1213, SM 1213, SM-1213
Chemical Properties
Molecular Weight305.37
FormulaC14H27NO6
Cas No.56824-20-5
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords